Clinical trials: Dendritic Cell
Non-small Cell Lung Cancer
Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer
Despite recent advances in the treatment of patients with resected NSCLC, disease recurrence and mortality related to lung cancer are common among patients with early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT01398124
- Testing
- Cyclin B1 Peptide
- Sponsor
- Milton S. Hershey Medical Center
Malignant Pleural Mesothelioma
Dendritic Cell-based Immunotherapy in Mesothelioma
Exploiting the immunostimulatory capacities of dendritic cells holds great promise for cancer immunotherapy. A mouse model for malignant mesothelioma allowed us to prove that autologous dendritic cells presenting tumor antigens…
- Trial name
- NCT00280982
- Testing
- tumor lysate-loaded autologous dendritic cells
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center
Lymphoma, Histiocytic Sarcoma
Pembrolizumab in Neoplasms or Lymphomas
This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Trial name
- NCT03316573
- Testing
- Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Kidney Cancer
Vaccine Therapy in Treating Patients With Kidney Cancer
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00014131
- Testing
- Biological/Vaccine: therapeutic autologous dendritic cells.
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lisata Therapeutics, Inc.
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
This phase I trial studies the side effects and best dose of autologous T-antigen-presenting cells (T-APC) vaccine following therapeutic autologous lymphocytes (CTL) and cyclophosphamide in treating patients with metastatic…
- Trial name
- NCT01339663
- Testing
- cyclophosphamide, aldesleukin, autologous tumor cell vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
CAR-T Followed by Bispecific Antibodies
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells.
- Trial name
- NCT04889716
- Testing
- mosunetuzumab, glofitamab, obinutuzumab
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non Small Cell Lung Cancer, Solid Tumor
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
- Trial name
- Luscid (NCT04571632)
- Testing
- Avelumab, Ipilimumab 5 MG/ML, Pembrolizumab 100 MG in 4 ML Injection
- Where
- 2 sites in Belgium
- Volunteers
- 36 people
- Sponsor
- Universitair Ziekenhuis Brussel
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00047021
- Testing
- sargramostim, cytarabine, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Progressive Solid Malignancies, Refractory Solid Malignancies
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Patients diagnosed with progressive and/or refractory solid malignancies, who have failed conventional therapy, and have no available, potentially curative therapeutic options, will be candidates for this Phase I/II study.
- Conditions
- Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer
- Trial name
- NCT02224599
- Testing
- TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Kiromic BioPharma Inc.
Lung Cancer
DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs
This is a single-center, single-arm, prospective clinical trial to investigate the safety and efficacy of Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
- Trial name
- NCT06329908
- Testing
- LG002
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhen-Yu Ding
Metastatic Pancreatic Carcinoma
A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma
This study is being done to determine whether it is possible to use an investigational vaccine that consists of dendritic cells in patients with pancreas cancer.
- Trial name
- NCT00843830
- Testing
- tumoral irradiation, Dendritic cell vaccination
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Renal Cell Carcinoma
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA…
- Trial name
- NCT04203901
- Testing
- CMN-001, Nivolumab+Ipilimumab, Lenvatinib+Everolimus
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- CoImmune
Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma
- Trial name
- NCT00057811
- Testing
- doxorubicin hydrochloride, cyclophosphamide, methotrexate
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Monoclonal Gammopathy, Smoldering Myeloma
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve…
- Conditions
- Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
- Trial name
- NCT03591614
- Testing
- DKK1
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Renal Cell Carcinoma
RNA-Loaded Dendritic Cell Cancer Vaccine
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
- Trial name
- NCT00087984
- Testing
- MB-002
- Where
- 5 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Argos Therapeutics
HIV Infection
Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus
The aim of this study was to assess tolerability and safety of three different formulations of an anti-HIV immunotherapy based on autologous dendritic cells (DCs) pulsed with HIV chemically inactivated with Aldrithiol™-2 (AT-2).
- Trial name
- NCT02766049
- Testing
- DC, DC10e6+HIV-AT2, DC10e7+HIV-AT2
- Volunteers
- 19 people
- Sponsor
- University of Sao Paulo General Hospital
Allergic Asthma, Allergy to Cats
Airway Immune Response to Allergens (Use Lay Language Here)
Most asthma is allergic in origin. The purpose of this study is to better understand the airway immune response to inhaled allergens in order to identify factors that promote asthma.
- Conditions
- Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis
- Trial name
- NCT04619017
- Testing
- Segmental allergen challenge
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- JOSALYN CHO
Metastatic Prostate Cancer
Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines
The purpose of this research is to develop a new and powerful type of immune therapy for prostate cancer patients. This therapy involves vaccinations with special stimulator cells found in the human body called dendritic cells.
- Trial name
- NCT01153113
- Testing
- hTERT mRNA DC
- Sponsor
- University of Florida